Is oxidized low-density lipoprotein present in vivo?

Current Opinion in Lipidology

Volumn 9, Issue 4, 1998, Pages 337-344

  Ylä Herttuala, Seppo ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; LOW DENSITY LIPOPROTEIN;

ANTIBODY BLOOD LEVEL; ARTICLE; ATHEROSCLEROSIS; AUTOIMMUNITY; HUMAN; LIPID OXIDATION; PATHOGENESIS; PRIORITY JOURNAL; VASCULAR DISEASE;

AUTOANTIBODIES; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; LIPOPROTEINS, LDL; MALE; T-LYMPHOCYTES;

EID: 0031662580     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199808000-00009     Document Type: Article

References (101)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362:801-809.
2. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991; 88:1785-1792.
3. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997; 272:20963-20966. An updated review concerning the role of Ox-LDL in atherogenesis.
4. Parthasarathy S, Wieland E, Steinberg D. A role for endothelial cell lipoxygenase in the oxidative modification of LDL. Proc Natl Acad Sci USA 1989; 86:1046-1050.
5. Belkner J, Wiesner R, Rathman J, Barnett J, Sigal E, Kühn H. Oxygenation of lipoproteins by mammalian lipoxygenases. Eur J Biochem 1993; 213:251-261.
6. Heinecke LW, Baker L, Rosen H, Chait A. Superoxide-mediated modification of low density lipoprotein by arterial smooth muscle cell. J Clin Invest 1986; 77:757-761.
7. Steinbrecher UP. Role of superoxide in endothelial-cell modification of low-density lipoproteins. Biochim Biophys Acta 1988; 959:20-30.
8. Esterbauer H, Gebicki J, Puhl H, Jurgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Rad Biol Med 1992; 13:341-390.
9. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Med Sci 1990; 87:1620-1624.
10. Darley-Usmar VM, Hogg N, O'Leary VJ, Wilson MT, Moncada S. The simultaneous generation of superoxide and nitric oxide can initiate lipid peroxidation in human low density lipoprotein. Free Rad Res Commun 1992; 17:9-20.
11. Balla G, Jacob HS, Eaton JW, Belcher JD, Vercellotti GM. Hemin - A possible physiological mediator of low density lipoprotein oxidation and endothelial injury. Arteriosclerosis Thromb 1991; 11:1700-1711.
12. Paganga G, Rice-Evans C, Rule R, Leake D. The interaction between ruptured erythrocytes and low-density lipoproteins. FEBS Lett 1992; 303:154-158.
13. Ehrenwald E, Chisolm GM Fox PL. Intact human ceruloplasmin oxidatively modifies low density lipoprotein. J Clin Invest 1994; 93:1493-1501.
14. Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994; 94:437-444.
15. Hazell LJ, van den Berg JJM, Stocker R. Oxidation of low-density lipoprotein by hypochlorite causes aggregation that is mediated by modification of lysine residues rather than lipid oxidation. Biochem J 1998; 302:297-304.
16. Smith C, Mitchinson MJ, Aruoma OI, Halliwell B. Stimulation of lipid peroxidation and hydroxyl-radical generation by the contents of human atherosclerotic lesions. Biochem J 1992; 286:901-905.
17. Kodama T, Freeman M, Rohrer L, Zabrecky J, Matsudaira P, Krieger M. Type I macrophage scavenger receptor contains α-helical and collagen-like coiled coils. Nature 1990; 343:531-535.
18. Hiltunen TP, Ylä-Herttuala S. Expression of lipoprotein receptors in atherosclerotic lesions. Atherosclerosis 1998; 137:81-88.
19. Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y, et al. An endothelial receptor for oxidized low-density lipoprotein. Nature 1997; 386:73-77. This study reports a new receptor cloned from endothelial cells which can bind and internalize Ox-LDL.
20. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara A. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci U S A 1993; 90:6434-6438.
21. Khoo JC, Miller E, McLoughlin P, Steinberg D. Enhanced macrophage uptake of low density lipoprotein after self-aggregation. Arteriosclerosis 1988; 8:348-358.
22. Kaartinen M, Penttilä A, Kovanen PT. Extracellular mast cell granules carry apolipoprotein B-100-containing lipoproteins into phagocytes in human arterial intima. Functional coupling of exocytosis and phagocytosis in neighboring cells. Arterioscler Thromb Vasc Biol 1995; 15:2047-2054.
23. Hurt E, Camejo G. Effect of arterial proteoglycans on the interaction of LDL with human monocyte-derived macrophages. Atherosclerosis 1987; 67:115-126.
24. de Graaf J, Hak-Lemmers HLM, Hectors MPC, Demacker PN, Hendriks JC, Stalenhoef AF. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 1991; 11:298-306.
25. Reaven P, Parthasarathy S, Grasse BJ, Miller E, Steinberg D, Witztum JL. Effects of oleate-rich and linoleate-rich diets on the susceptibility of low density lipoprotein to oxidative modification in mildly hypercholesterolemic subjects. J Clin Invest 1993; 91:668-676.
26. Ylä-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989; 84:1086-1095.
27. Ylä-Herttuala S, Jaakkola O, Ehnholm C, Tikkanen MJ, Solakivi T, Särkioja T, Nikkari T. Characterization of two lipoproteins containing apolipoproteins B and E from lesion-free human aortic intima. J Lipid Res 1988; 29:563-572.
28. Haberland ME, Fong D, Cheng L. Malondialdehyde-altered LDL occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science 1988; 241:215-218.
29. Palinski W, Rosenfeld ME, Ylä-Herttuala S, Gurtner GC, Socher SS, Butler SW, et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci U S A 1989; 86:1372-1376.
30. Boyd HC, Gown AM, Wolfbauer G, Chait A. Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit. Am J Pathol 1989; 135:815-825.
31. Rosenfeld ME, Palinski W, Ylä-Herttuala S, Butler S, Witztum JL. Distribution of oxidation specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis 1990; 10:336-349.
32. Ylä-Herttuala S, Butler S, Picard S, Palinski W, Steinberg D, Witztum JL. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb 1994; 14:32-40.
33. Salonen JT, Ylä-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992; 339:883-887.
34. Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that anti-oxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks slowing the progression of atherosclerosis in the WHHL rabbit. Proc Natl Acad Sci U S A 1987; 84:7725-7729.
35. Kita T, Nagano Y, Yokode M, Ishii K, Kume N, Ooshima A, et al. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci U S A 1987; 84:5928-5931.
36. Steinberg D, Lewis A. Conner Memorial Lecture. Oxidative modification of LDL and atherogenesis. Circulation 1997; 95:1062-1071.
37. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA. et al. Atherosclerosis, basic mechanisms: oxidation, inflammation, and genetics. Circulation 1995; 91:2488-2496.
38. Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci U S A 1987; 84:2995-2999.
39. Chisolm GM. Cytotoxicity of oxidized lipoproteins. Curr Opin Lipidol 1991; 2:311-316.
40. Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 1990; 344:160-162.
41. Ares MPS, Kallin B, Eriksson P, Nilsson J. Oxidized low-density lipoprotein induces transcription factor activator protein-1 but inhibits activation of nuclear factor-κB in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1995; 15:1584-1590.
42. Kinscherf R, Claus R, Wagner M, Gehrke C, Kamencic H, Hou D, et al. Apoptosis caused by oxidized LDL is manganese superoxide dismutase and p53 dependent. FASEB J 1998; 12:461-467. This article describes some mechanisms which are associated to apoptosis induced by Ox-LDL.
43. Nagy L, Tontonoz P, Alvarez JGA, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell 1998; 93:229-240. This article describes a new mechanism whereby Ox-LDL affects gene expression through activation of PPARγ.
44. de Rijke YB, van Berkel TJC. Rat liver Kupffer and endothelial cells express different binding proteins for modified low density lipoproteins. J Biol Chem 1994; 14:824-827.
45. Hodis HN, Kramsch DM, Avogaro P, Bittolo-Bon G, Cazzolato G, Hwang J, et al. Biochemical and cytotoxic characteristics of an in vivo circulating oxidized low density lipoprotein (LDL). J Lipid Res 1994; 35:669-677.
46. Palinski W, Hörkkö S, Miller E, Steinbrecher UP, Powell HC, Curtiss LK, Witztum JL. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoproteins E-deficient mice. J Clin Invest 1996; 98:800-814.
47. Holvoet P, Stassen J-M, Van Cleemput J, Collen D, Vanhaecke J. Oxidized low density lipoproteins in patients with transplant-associated coronary artery disease. Arterioscler Thromb Vasc Biol 1998; 18:100-107.
48. Ylä-Herrtuala S, Palinski W, Rosenfeld ME, Steinberg D, Witztum JL. Lipoproteins in normal and atherosclerotic aorta. Eur Heart J 1990; 11:88-99.
49. Hoff HF, O'Neill J. Lesion-derived low density lipoprotein and oxidized low density lipoprotein share a liability for aggregation leading to enhanced macrophage degradation. Arteriosclerosis Thromb 1991; 11:1209-1222.
50. Steinbrecher UP, Lougheed M. Scavenger receptor-independent stimulation of cholesterol esterification in macrophages by low density lipoprotein extracted from human aortic intima. Arteriosclerosis Thromb 1992; 12:608-625.
51. Mora R, Simionescu M, Simionescu N. Purification and characterization of extracellular liposomes isolated from the hyperlipidemic rabbit aorta. J Lipid Res 1990; 31:1793-1807.
52. Daugherty A, Zweifel BS, Sobel BE, Schonfeld G. Isolation of low density lipoprotein from atherosclerotic vascular tissue of Watanabe heritable hyperlipidemic rabbits. Arteriosclerosis 1988; 8:768-777.
53. Rapp JH, Harris HW, Hamilton RL, Krupski WC, Reilly LM, Ehrenfeld WK, et al. Particle size distribution of lipoproteins from human atherosclerotic plaque: a preliminary report. J Vasc Surg 1989; 4:81-88.
54. Chao F-F, Blanchette-Mackie EJ, Chen Y-J, Dickens BF, Berlin E, Amende LM, et al. Characterization of two unique cholesterol-rich lipid particles isolated from human atherosclerotic lesions. Am J Pathol 1990; 136:169-179.
55. Guyton JR, Klemp KF. Early extracellular and cellular lipid deposits in aorta of cholesterol-fed rabbits. Am J Pathol 1992; 141:925-936.
56. Torzewski M, Klouche M, Hock J, Messner M, Dorweiler B, Torzewski J, et al. Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. Arterioscler Thromb Vasc Biol 1998; 18:369-378.
57. Calara F, Dimayuga P, Niemann A, Thyberg J, Diczfalusy U, Witztum JL, et al. An animal model to study local oxidation of LDL and its biological effect in the arterial wall. Arterioscler Thromb Vasc Biol 1998; 884-893.
58. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci U S A 1995; 92:3893-3897.
59. Mironova M, Virella G, Lopes-Virella MF. Isolation and characterization of human antioxidized LDL autoantibodies. Arterioscler Thromb Vasc Biol 1996; 16:222-229.
60. Maggi E, Chiesa R, Melissano G, Castellano R, Astore D, Grossi A, et al. LDL oxidation in patients with severe carotid atherosclerosis. Arterioscler Thromb 1994; 14:1892-1899.
61. Iribarren C, Folsom AR, Jacobs DR Jr, Gross MD, Belcher JD, Eckfeldt JH. Association of serum vitamin levels, LDL, susceptibility to oxidation, and autoantibodies against MDA-LDL with carotid atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17:1171-1177.
62. Virella G, Virella I, Leman RB, Pryor MB, Lopes-Virella MF. Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers. Int J Clin Lab Res 1993; 23:95-101.
63. Puurunen M, Mänttäri M, Manninen V, Tenkanen L, Alfthan G, Ehnholm C, et al. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med 1994; 154:2605-2609.
64. van de Vijver LPL, Steyger R, van Poppel G, Boer JMA, Kruijssen DACM, Seidell JC, et al. Autoantibodies against MDA-LDL in subjects with severe and minor atherosclerosis and healthy population controls. Atherosclerosis 1996; 122:245-253.
65. Ben-Yehuda O, Witztum JL, Keaney JF Jr, Frei B, Hankin B, Vita JA. Autoantibody titer to malondialdehyde modified low density lipoprotein correlates with extent of coronary artery disease. Circulation 1996; 94(Suppl 1):1-638.
66. Wu R, Nityanand S, Berglund L, Lithell H, Holm G, Lefvert AK. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler Thromb Vasc Biol 1997; 17:3159-3163. This is a long follow-up study which suggests that autoantibodies against Ox-LDL predict myocardial infarction.
67. Bellomo G, Maggi E, Poli M, Agosta FG, Bollati P, Finardi G. Autoantibodies against oxidatively modified low-density lipoproteins in NIDDM. Diabetes 1995; 44:60-66.
68. Uusitupa M, Niskanen L, Luoma J, Mercuri M, Rauramaa R, Vilja P, Ylä-Herttuala S. Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1996; 16:1236-1242.
69. Eber B, Schumacher M, Tatzber F, Kaufmann P, Luha O, Esterbauer H, et al. Autoantibodies to oxidized low density lipoproteins in restenosis following coronary angioplasty. Cardiology 1994; 84:310-315.
70. Bergmark C, Wu R, de Faire U, Lefvert AK, Swedenborg J. Patients with early onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler Thromb Vasc Biol 1995; 15:441-445.
71. Heitzer T, Ylä-Herttuala S, Luoma J, Kurz S, Münzel T, Olschewski M, et al. Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia: role of oxidized LDL. Circulation 1996; 93:1346-1353.
72. Raitakari O, Pitkänen O-P, Lehtimäki T, Lahdenperä S, Iida H, Ylä-Herttuala S, et al. In vivo low density lipoprotein oxidation relates to coronary reactivity in young men. J Am Coll Cardiol 1997; 30:97-102.
73. Parums DV, Brown DL, Mitchinson MJ. Serum antibodies to oxidized low-density lipoprotein and ceroid in chronic periaortitis. Arch Pathol Lab Med 1990; 114:383-387.
74. Branch DW, Mitchell MD, Miller E, Palinski W, Witztum JL. Pre-eclampsia and serum antibodies to oxidised low-density lipoprotein. Lancet 1994; 343:645-646.
75. Heikkinen A-M, Niskanen L, Ylä-Herttuala S, Luoma JS, Tuppurainen MT, Komulainen M, et al. Postmenopausal hormone replacement therapy and autoantibodies against oxidized LDL. Maturitas 1998; in press.
76. Hörkkö S, Miller E, Dudl E, Reaven P, Curtiss LK, Zvaifler NJ, et al. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. J Clin Invest 1996; 98:815-825.
77. Palinski W, Miller E, Witztum JL. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci USA 1995; 92:821-825.
78. Ameli S, Hultgàrdh-Nilsson A, Regnström J, Calara F, Yano J, Cercek B, et al. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 1996; 16:1074-1079.
79. Salonen JT, Nyyssönen K, Salonen R, Porkkala-Sarataho E, Tuomainen T-P, Diczfalusy U, et al. Lipoprotein oxidation and progression of carotid atherosclerosis. Circulation 1997; 85:840-845. This study reports that cholesterol oxidation products predict intimai thickening in carotid arteries.
80. Regnström J, Nilsson J, Tornvall P, Landou C, Hamsten A. Susceptibility of low-density lipoprotein to oxidation and coronary atherosclerosis in man. Lancet 1992; 339:1183-1186.
81. Walldius G, Erikson U, Olsson AG, Bergstrand L, Hådell K, Johansson J, et al. The effect of probucol on femoral atherosclerosis: the probucol quantitative regression Swedish trial (PQRST). Am J Cardiol 1994; 74:875-883.
82. Gey KF, Puska P, Jordan P, Moser UK. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. Amer J Clin Nutr 1991; 53:326S-334S.
83. Riemersma RA, Wood DA, MacIntyre CCA, Elton RA, Gey KF, Oliver MF. Risk of angina pectoris and plasma concentrations of vitamins A. C. and E and carotene. Lancet 1991; 337:1-5.
84. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. New Engl J Med 1993; 328:1444-1449.
85. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. New Engl J Med 1993; 328:1450-1456.
86. Knekt P, Reunanen A, Järvinen R, Seppanen R, Heliövaara M, Aromaa A. Antioxidant vitamin intake and coronary mortality in a longitudinal population study. Am J Epidemiol 1994; 139:1180-1189.
87. Kushi LH, Folsom AR, Prineas RJ, Mink PJ, Wu Y, Bostick RM. Dietary antioxidant vitamins and death from coronary heart disease in post-menopausal women. New Engl J Med 1996; 334:1156-62.
88. Enstrom JE, Kanim LE, Klein MA. Vitamin C intake and mortality among a sample of the United States population. Epidemiology 1992; 3:194-202.
89. Hertog MGL, Feskens EJM, Hollman PCH, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen elderly study. Lancet 1993; 342:1007-1011.
90. Blot WJ, Li J-Y, Taylor PR, Guo W, Dawsey S, Wang GQ, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993; 85:1483-1492.
91. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. New Engl J Med 1994; 330:1029-1035.
92. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. New Engl J Med 1996; 334:1150-1155.
93. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. New Engl J Med 1996; 334:1145-1149.
94. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ, Brown MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347:781-786.
95. Rapola JM, Virtamo J, Ripatti S, Huttunen JK, Albanes D, Taylor PR, et al. Randomised trial of α-tocopherol and β-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet 1997; 349:1715-1720.
96. Salonen JT, Alfthan G, Huttunen JK, Pikkarainen J, Puska P. Association between cardiovascular death and myocardial infarction and serum selenium in a matched-pair longitudinal study. Lancet 1982; 2:175-179.
97. Suadicani P, Hein HO, Gyntelberg F. Serum selenium concentration and risk of ischaemic heart disease in a prospective cohort study of 3000 males. Atherosclerosis 1992; 96:33-42.
98. Salonen JT, Nyyssönen K, Korpela H, Tuomilehto J, Seppänen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 1992; 86:803-811.
99. Magnusson MK, Sigfusson N, Sigvaldason H, Johannesson GM, Magnusson S, Thorgeirsson G. Low iron-binding capacity as a risk factor for myocardial infarction. Circulation 1994; 89:102-108.
100. Sempos CT, Looker AC, Gillium RF, Makuc DM. Body iron stores and the risk of coronary heart disease. New Engl J Med 1994; 330:1119-1124.
101. Diaz MN, Frei B, Vita JA, Keaney JF. Antioxidants and atherosclerotic heart disease. New Engl J Med 1997; 337:408-416.